In this episode of Boston Scientific Talks, Boston Scientific's electrophysiology leaders, Ken Stein, MD, SVP, Global Chief Medical Officer and Nick Spadea-Anello, Global President of Electrophysiology, offer a deep dive into the transformative potential of the FARAPULSE Pulsed Field Ablation System. They discuss the strategic development and clinical advantages of this innovative technology, emphasizing its ability to target cardiac tissue while minimizing the risk of collateral damage to vital structures like the esophagus.

The duo also explores the synergistic potential of combining PFA with devices like the WATCHMAN for stroke prevention, painting a picture of a more streamlined, patient-centric approach to cardiac care. With a keen eye on the future, they discuss the vision for expanding PFA's applications, including its role in treating a broader spectrum of arrhythmias and its adaptability to various procedural settings. Tune in to learn more about Boston Scientific's forward-thinking approach to cardiac ablation.

Thank you to Dassault Systèmes for sponsoring this episode. To learn how Dassault Systèmes enables innovation in medtech, visit www.medtecheco.com/lifecycle. 

Thank you for listening to the Boston Scientific Podcast.

Subscribe to this podcast on every major podcast platform.

Boston Scientific's EP leaders Stein and Spadea-Anello discuss the next leap in cardiac ablation

In this episode of AbbottTalks, Sandra Lesenfants, SVP of Abbott’s structural heart business, discusses the latest advancements in structural heart care, focusing on Abbott's transformative TriClip device for tricuspid regurgitation.

Lesenfants highlights Abbott’s commitment to patient-centered innovation, emphasizing the importance of creating solutions that meet patients’ needs through safe and effective technologies. She also shares Abbott’s approach to expanding access to minimally invasive therapies, particularly in underserved populations worldwide, and the role of physician partnerships in advancing structural heart interventions.

Lastly, Lesenfants underscores the company’s efforts to increase diversity in clinical trials, noting the importance of intentional inclusivity across gender and ethnicity to better serve diverse patient populations.

Thank you to Confluent Medical Technologies for sponsoring this episode of AbbottTalks. For more information on how Confluent Medical works with medical device companies, visit https://confluentmedical.com/.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Lesenfants shares TriClip progress, patient-centered innovation & clinical trial diversity

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

Boston Scientific's EP leaders Stein and Spadea-Anello discuss the next leap in cardiac ablation

DeviceTalks

Related tracks